Exevir adds to series A, stresses need for second-generation COVID-19 antibodies March 16, 2021 By Nuala Moran No Comments LONDON – Exevir Bio NV added a further €15 million (US$17.9 million) to close its series A round at €42 million, providing the means to take its nanobody therapy for treating COVID-19 infection through to registration.Read More